|Day Low/High||43.24 / 43.90|
|52 Wk Low/High||36.00 / 51.24|
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Abbott Laboratories has taken over the #84 spot from Simon Property Group, Inc. , according to ETF Channel.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Abbott’s (ABT) stock price target was increased to $50 from $48 at Barclays following the company’s 2016 second quarter results.
The medical device company has two pending acquisitions worth just under $40 billion combined.
The company reported flat but in line earnings of $1.06 per share.
Abbott Labs (ABT) 2016 second quarter results surpassed analysts’ expectations.
Trade-Ideas LLC identified Abbott Laboratories (ABT) as a post-market leader candidate
Abbott Labs (ABT) will report 2016 second quarter earnings on Wednesday, July 20 before the market opens.
Abbott Labs -- with its 2.5% dividend yield and market underperformance -- will look safer when the market begins to rotate out of hotter stocks.
Can medical technology stocks continue their momentum higher in the second half of the year? Investors say yes, but technical analysis says not necessarily.
Abbott Labs (ABT) is scheduled to report 2016 second-quarter financial results before the market open on Wednesday.
Jim Cramer will be watching a host of earnings next week. In addition, he offers his playbook for financial literacy.
Wedbush analyst Tao Levy also does not expect to see rival offers to emerge for St. Jude Medical.
- Approval includes Toric version of Symfony IOL for people with astigmatism
TheStreet highlights 3 stocks pushing the health services industry lower today.
Abbott Labs (ABT) absorbable stent, which was approved by the FDA last week, has gone into its first patients.
Oil began to rebound Wednesday from steep declines earlier this week.
Abbott Laboratories (ABT) won approval for an absorbable stent this morning, but the stock is falling.
- Revolutionary device made of naturally dissolving material
Following Brexit volatility, Deutsche Bank offered investors 42 best long ideas; here's the 12 stocks from the list with the highest dividend yields.
They should wait until the rally appears to be running out of steam in order to go in on the short side.
Engaged Capital agitated against the cardiac medical device maker's buy of an Israeli company and pushed for a new board member that once led the acquirer's M&A efforts.
Cramer likes Abbott Labs and United Technology but is no fan of Nevsun Resources.
There are way too many companies but the U.S. government has thrown a chill into M&A, Cramer says.
Trade-Ideas LLC identified Abbott Laboratories (ABT) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Shares of Abbott Laboratories (ABT) are lower on Tuesday but Jefferies increased its price target on the stock, advising investors to 'be patient.'